Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;33(31):e2007630.
doi: 10.1002/adma.202007630. Epub 2021 May 28.

Recent Advances in Engineered Materials for Immunotherapy-Involved Combination Cancer Therapy

Affiliations
Review

Recent Advances in Engineered Materials for Immunotherapy-Involved Combination Cancer Therapy

Jun-Long Liang et al. Adv Mater. 2021 Aug.

Abstract

Immunotherapy that can activate immunity or enhance the immunogenicity of tumors has emerged as one of the most effective methods for cancer therapy. Nevertheless, single-mode immunotherapy is still confronted with several critical challenges, such as the low immune response, the low tumor infiltration, and the complex immunosuppression tumor microenvironment. Recently, the combination of immunotherapy with other therapeutic modalities has emerged as a powerful strategy to augment the therapeutic outcome in fighting against cancer. In this review, recent research advances of the combination of immunotherapy with chemotherapy, phototherapy, radiotherapy, sonodynamic therapy, metabolic therapy, and microwave thermotherapy are summarized. Critical challenges and future research direction of immunotherapy-based cancer therapeutic strategy are also discussed.

Keywords: cancer; combination therapy; engineered materials; immunotherapy; synergistic effect.

PubMed Disclaimer

References

    1. a) D. J. Irvine, E. L. Dane, Nat. Rev. Immunol. 2020, 20, 321;
    1. b) S. Yang, T. Lammers, Acc. Chem. Res. 2019, 52, 1543;
    1. c) S. L. Topalian, J. M. Taube, D. M. Pardoll, Science 2020, 367, 6477;
    1. d) M. Chen, G. Quan, T. Wen, P. Yang, W. Qin, H. Mai, Y. Sun, C. Lu, X. Pan, C. Wu, ACS Appl. Mater. Interfaces 2020, 12, 32259.
    1. a) R. S. Riley, C. H. June, R. Langer, M. J. Mitchell, Nat. Rev. Drug Discovery 2019, 18, 175;

LinkOut - more resources